AGP Executive Report
Last update: 8 hours agoFDA Approvals: The FDA cleared adjuvant belzutifan (Welireg) plus pembrolizumab (Keytruda) for clear cell renal cell carcinoma after nephrectomy in intermediate/high recurrence-risk patients, backed by the LITESPARK-022 trial. Oncology Pipeline: AstraZeneca won FDA approval for capivasertib (Truqap) plus abiraterone and prednisone for PTEN-deficient metastatic hormone-sensitive prostate cancer, while Jazz’s Zepzelca (lurbinectedin) missed the main goal in a Phase III second-line small cell lung cancer study, putting its accelerated approval at risk. Medtech M&A: Deal momentum stayed strong in 2026, with major moves including Boston Scientific’s Penumbra bid and Abbott’s Exact Sciences tie-up, plus continued acquisitions and divestitures across the sector. Healthcare Access & Policy: CMS published final rules for accrediting organizations and HHS OIG flagged high denial rates for Medicare Advantage prior authorizations for long-term acute care and rehab. AI in Care: Research warns that “pushy” healthcare chatbots can reduce patient willingness to attend screening, and a separate report highlights friction when chatbots mimic humans without clear transparency. Public Health: The U.S. expanded Ebola countermeasure funding by $50M via CEPI, while India reported no new Nipah cases but kept quarantine and monitoring active.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS]]>](https://cdn.sanity.io/images/0vv8moc6/modernretina/c341a799a5425c9326ac6d2b79d5950c2b00e065-1280x720.jpg)
